Potential Role of Acupuncture Treatment in Neuronal and Network Dysfunction in Patients With Vascular Cognitive Impairment
Vascular cognitive impairment (VCI) is a broad dimensional term, ranging from mild cognitive impairment without incapacity on activity of daily living to vascular dementia (VaD), referred to as significant cognitive impairment and decline in function status.
In this three-year project, we aim to evaluate the effects of biochemical data, early clinical variables, neuroimaging results, and intervention of acupuncture treatment on vascular event related cognitive impairment in crossectional analysis and longitudinal follow-up.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Stroke is a common cerebrovascular disease of the central nervous system leading to serious medical complication. It results in a high mortality rate and increased disability rate. Stroke survivors may have long-lasting consequences, including motor dysfunction, sensibility dysfunction, and cognitive impairment]. Cognition is a key component of rehabilitation and recovery; therefore it is associated with poor engagement in rehabilitee and outcomes including increased mortality. As vascular dementia (VaD) is considered the second-most-common type of dementing illness, accounting for a significant proportion of total dementia case, vascular cognitive impairment (VCI) is a broader dimensional term, ranging from mild cognitive impairment without incapacity on activity of daily living to VaD, referred to as significant cognitive impairment and decline in function status.
Acupuncture is an ancient Chinese medical technique in which fine, stainless steel needles are inserted into certain anatomical locations of the body surface to elicit neurohormonal responses of the body system via nerve stimulation. Acupuncture are reported to be probably effective in improving cognitive function in vascular dementia animal models via multiple mechanisms such as anti-apoptosis, antioxidative stress reaction, and metabolism enhancing of glucose and oxygen.
Motor features may not parallel to the cognitive changes, it will serve as the disease progression marker. Unified Parkinson's Disease Rating Scale (UPDRS)-part III scores and NIH Stroke Scale (NIHSS) will be used.
- At Kaohsiung Chang Gung Memorial Hospital, all the patients (n=80) will be included and receive a Standardized Acupuncture intervention; 40 will be treated with regular medication; 40 will be treated with acupuncture and regular medication.
- For acupressure program, all participants are treated in supine position, and a certified TCM physician applied firm pressure (3 to 5 kg of pressure) with fingertips in a circular motion at a speed of 2 circles per second for a duration of one minute per acupoint. The complete process lasts for 8 minutes.
Cognitive function, Motor function, Mood and Sleep will be evaluated at baseline and follow-up period of time at 3 month, 6 month, and 12 month.
Tipo de estudio
Inscripción (Anticipado)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Kaohsiung, Taiwán, 83301
- Reclutamiento
- Kaohsiung Chang Gung Memorial Hospital
-
Contacto:
- YaTing Chang
- Número de teléfono: 077317123
- Correo electrónico: emily0606@cgmh.org.tw
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
1. Fulfill the diagnostic criteria of vascular cognitive impairment
Exclusion Criteria:
- Systemic inflammatory disease with on-going treatment
- Severe psychiatric disease, such as major depressive disorder or schizophrenia
- Severe traumatic brain injury
- Unable to tolerate exam of brain MRI
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador falso: regular medication treatment
|
acupuncture treatment on selected acupoint
|
|
Experimental: acupuncture and regular medication treatment
|
acupuncture treatment on selected acupoint
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from baseline sleep quality at 3 months, 6 months, 12 months
Periodo de tiempo: 3 months, 6 months, 12 months
|
Analogous variables were extracted from actigraphy.
The sleep variables collected were sleep start time, sleep end time, sleep duration, sleep efficiency, and wake after sleep onset time, and the activity variables collected were heart rate activity score,activity amount, and activity intensity
|
3 months, 6 months, 12 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from baseline neuro-behavioral performances at 3 months, 6 months, 12 months
Periodo de tiempo: 3 months, 6 months, 12 months
|
Cognitive Abilities Screening Instrument (CASI).
In addition to general cognitive performance, CASI was used to evaluate specific domains, including short-term memory, attention and concentration, abstraction, visual construction, language, and list-generating fluency.
|
3 months, 6 months, 12 months
|
|
Change from baseline motor function (UPDRS) at 3 months, 6 months, 12 months
Periodo de tiempo: 3 months, 6 months, 12 months
|
Unified Parkinson's Disease Rating Scale (UPDRS)-part III scores for parkinsonian features.
|
3 months, 6 months, 12 months
|
|
Change from baseline motor function (NIHSS) at 3 months, 6 months, 12 months
Periodo de tiempo: 3 months, 6 months, 12 months
|
NIH Stroke Scale (NIHSS) score 0-24.
|
3 months, 6 months, 12 months
|
|
Change from baseline continuous motor function at 3 months, 6 months, 12 months
Periodo de tiempo: 3 months, 6 months, 12 months
|
Physical activity was measured using accelerometers.
|
3 months, 6 months, 12 months
|
|
Change from baseline memory performances at 3 months, 6 months, 12 months
Periodo de tiempo: 3 months, 6 months, 12 months
|
Verbal memory were evaluated by using Chinese Version Verbal Learning Test (CVVLT).Visual-spatial abilities.
|
3 months, 6 months, 12 months
|
|
Change from baseline executive performances at 3 months, 6 months, 12 months
Periodo de tiempo: 3 months, 6 months, 12 months
|
Attention and executive function was evaluated by Trail Making Test B.
|
3 months, 6 months, 12 months
|
|
Change from baseline executive performances (Stroop interference test) at 3 months, 6 months, 12 months
Periodo de tiempo: 3 months, 6 months, 12 months
|
Attention and executive function was evaluated by Stroop interference test.
|
3 months, 6 months, 12 months
|
|
Change from baseline executive performances (calculation) at 3 months, 6 months, 12 months
Periodo de tiempo: 3 months, 6 months, 12 months
|
As the calculation ability depends on executive function, calculation ability was evaluated to reflect part of executive function.
|
3 months, 6 months, 12 months
|
|
Change from baseline abstract thinking at 3 months, 6 months, 12 months
Periodo de tiempo: 3 months, 6 months, 12 months
|
Abstract reasoning was evaluated by using similarities (conceptualization) in frontal assessment battery-Similarities.
|
3 months, 6 months, 12 months
|
|
Change from baseline language performances at 3 months, 6 months, 12 months
Periodo de tiempo: 3 months, 6 months, 12 months
|
Boston Naming Test were used to evaluate language ability in naming.
|
3 months, 6 months, 12 months
|
|
Change from baseline fluency performances at 3 months, 6 months, 12 months
Periodo de tiempo: 3 months, 6 months, 12 months
|
Semantic category fluency.
|
3 months, 6 months, 12 months
|
|
Change from baseline neuropsychiatric symptoms at 3 months, 6 months, 12 months
Periodo de tiempo: 3 months, 6 months, 12 months
|
The neuropsychiatric symptoms of the participants were measured using the Neuropsychiatric Inventory.
|
3 months, 6 months, 12 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: YaTing Chang, MD,PhD, Chang Gung Memorial Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 201802103A3
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .